Shares of Edgewise Therapeutics, Inc. (EWTX) are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.
For the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.
While Edgewise continues to operate at a loss as it develops its pipeline of therapeutics, the earnings beat has fueled investor optimism and driven the stock higher in premarket trading. The strong performance follows a 37.2% gain for EWTX shares during the third quarter and a remarkable 234.7% increase so far this year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。